|
|
 |
|
Viewing report
|
|
 |
 |
In Vitro Diagnostic Companies Analysis
Espicom Business Intelligence Ltd, Sep 2007, Pages: 166
This new report from provides an evaluation of the products, alliances and performance of over 30 leading global players.
Evaluation of the products, alliances and performance of over 30 leading global players.
HUGE POTENTIAL
The global market for in vitro diagnostics (IVD) in 2007 is estimated to be US$34 billion and we expect growth to be around 9% annually.
Although in vitro diagnostics influence more than 60% of clinical decisions, IVD sales represent only a small proportion of total healthcare expenditures; in 2005 IVD sales in Europe totalled less that 2% of total healthcare expenditure. However, clinicians are under increasing pressure for better clinical outcomes and to control cost through efficient disease management. The early detection and treatment of long-term conditions is critical, and modern, fast and effective diagnostics are essential to meeting these aims.
INNOVATION IS DRIVING CHANGE
For example, molecular diagnostics is the fastest growing segment of clinical diagnostics with a growth rate of around 10-15% and is estimated to be worth approximately US$2.4 billion.
By detecting DNA and RNA sequences characteristic of bacteria, viruses or cells, molecular diagnostics has applications in a wide variety of disorders including infectious diseases, cancer and cardiovascular. Molecular diagnostic testing is often complex and usually carried out in a lab environment. The trend and challenge is to create testing products which provide fast and accurate results in a clinical setting.
This is a competitively hot area with Beckman Coulter, Becton Dickinson, Siemens, bioMérieux, Roche and Gen-Probe all involved.
Customers who bought this item also bought
High Growth Diagnostics: Technology and Market Analyses
Clinical Chemistry Analyzers and Reagents - Global Strategic Business Report
Molecular Diagnostics: Transforming Pharmaceuticals, Impacting New Markets
Forest Laboratories: Pipeline - Products - Performance - Potential
Molecular Diagnostics Markets
Bristol-Myers Squibb: Pipeline - Products - Performance - Potential
Clinical Laboratory Testing Volume 1: Reagents and Instruments
Eli Lilly - Pipeline - Products - Performance - Potential
|
 |
|
|